141 – 150 of 230
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
Predicting clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid concentrations of extracellular matrix proteins in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status
(
- Contribution to journal › Article
-
Mark
Method comparison study of the Elecsys® β-Amyloid (1–42) CSF assay versus comparator assays and LC-MS/MS
(
- Contribution to journal › Article
-
Mark
The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk
(
- Contribution to journal › Article
-
Mark
Neurogranin as a potential synaptic marker in the cerebrospinal fluid of patients with a first episode psychosis
(
- Contribution to journal › Letter
-
Mark
CSF placental growth factor – a novel candidate biomarker of frontotemporal dementia
(
- Contribution to journal › Article
-
Mark
Elecsys® Total-Tau and Phospho-Tau (181P) CSF assays : Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid
(
- Contribution to journal › Article
-
Mark
CSF and blood biomarkers for Parkinson's disease
(
- Contribution to journal › Scientific review
-
Mark
Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia : An elusive quest
(
- Contribution to journal › Article